EML4 and non-small cell lung carcinoma: Molecular diagnostic testing has provided us with an increased understanding of the cancer biology, which has recently enabled the development of molecular-based targeted therapies such as vemurafenib (Zelboraf®, Roche/Genentech) for melanoma patients harboring a BRAF V600E mutation (6), and crizotinib (Xalkori®, Pfizer) and ceritinib (Zykadia®, Novartis), for non-small cell lung cancer (NSCLC) patients with EML4–ALK translocation (7, 8).